<DOC>
	<DOCNO>NCT01818986</DOCNO>
	<brief_summary>In i-SABR ( immunotherapy + Stereotactic Ablative Body Radiation ) trial , stereotactic radiation multiple metastatic site deliver eradicate site bulky progressive disease , also provide antigen presentation immune stimulation expect act synergistically concurrently administer immunotherapy Sipuleucel-T thereby significantly improve treatment outcome metastatic castrate resistant prostate cancer patient ( mCRPC ) . Both Sipuleucel-T SABR FDA approve therapeutic cancer treatment</brief_summary>
	<brief_title>Sipuleucel-T Stereotactic Ablative Body Radiation ( SABR ) Metastatic Castrate-resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Biopsy proven prostate cancer 2 . Patient must currently androgen deprivation antiandrogen therapy castrate level testosterone ( &lt; 50ng/dl ) . Medical castration continue disease progression 3 . Radiographic evidence metastatic disease document bone scan CT scan . Patients number metastatic site allow enroll . However , six site select SBRT treatment , discretion treat radiation oncologist . 4 . PSA ≥ 5 ng/ml 5 . Asymptomatic minimally symptomatic patients1 . Visual Analog Scale ( VAS ) ≤ 4 ; vNo narcotic use last 21 day 6 . Adequate hematologic , renal , liver function 7 . Previous treatment surgery , radiation hormonal therapy allow . 8 . Performance status ECOG 0 1 . 9 . Life expectancy least 6 month 10 . Negative serology test human immunodeficiency virus ( HIV ) 1 2 , human T cell lymphotropic virus ( HTLV ) 1 , Hepatitis B C. 11 . Age ≥ 18 year . 12 . Ability understand willingness sign write informed consent 1 . Subjects must two different regiment chemotherapy previously chemotherapy within past three month . 2 . Subjects may receive investigational agent treatment prostate cancer . 3 . Subjects know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 4 . Subjects malignant pleural effusion malignant ascites 5 . Systemic corticosteroid use within past 28 day . Use inhale , intranasal , topical steroid acceptable . 6 . Systemic immunosuppressive therapy past 28 day . 7 . Use follow within past 28 day : Megestrol acetate ( Megace® ) , diethyl stilbestrol ( DES ) , cyproterone acetate , Ketoconazole , high dose calcitriol [ 1,25 ( OH ) 2VitD ] ( i.e. , &gt; 7.0 μg/week ) . 8 . Inability tolerate contrast dye baseline CT imaging . 9 . Initiation discontinuation biphosphonate use within past 28 day . 10 . Subjects pathologic longbone fracture 11 . Subjects spinal cord compression 12 . Paget 's disease bone . 13 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>